LimmaTech Biologics, a Schilieren, Switzerland-based biotech company developing next-generation vaccines to prevent life-threatening diseases, raised $37M in Series A funding.
the round was led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. Concurrent with the financing, Kabeer Aziz from Adjuvant Capital, Zina Affas Besse, PhD, from AXA IM Alts, and Camilla Petrycer Hansen, PhD from Novo Holdings will join LimmaTech’s Board of Directors.
Led by CEO Dr. Franz-Werner Haas, LimmaTech Biologics is applying its know-how of engineering complex molecules to develop vaccines to prevent life-threatening diseases. Spun out from GlycoVaxyn after that company’s acquisition by GSK, LimmaTech is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance such as gonorrhea, alongside partnered programs with GSK.
The company intends to use the funds to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosisandgonorrhea.
Later-stage clinical development efforts will focus on the Shigella vaccine program, which LimmaTech developed as part of a joint collaboration with GSK and recently exclusively in-licensed. The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023.
FinSMEs
09/10/2023